603998 方盛制药
已收盘 02-06 15:00:00
资讯
新帖
简况
方盛制药(603998.SH)控股子公司获得《药品生产许可证》
智通财经 · 02-05 16:05
方盛制药(603998.SH)控股子公司获得《药品生产许可证》
方盛制药(603998)披露并购基金对外出售投资项目部分股份进展公告,2月2日股价下跌1.44%
证券之星 · 02-02
方盛制药(603998)披露并购基金对外出售投资项目部分股份进展公告,2月2日股价下跌1.44%
每周股票复盘:方盛制药(603998)洛索洛芬钠凝胶贴膏获准生产
证券之星 · 02-01
每周股票复盘:方盛制药(603998)洛索洛芬钠凝胶贴膏获准生产
方盛制药(603998)披露关于受让药品上市许可的进展公告,1月28日股价下跌2.37%
证券之星 · 01-28
方盛制药(603998)披露关于受让药品上市许可的进展公告,1月28日股价下跌2.37%
方盛制药最新公告:洛索洛芬钠凝胶贴膏获得药品注册证书
证券之星 · 01-25
方盛制药最新公告:洛索洛芬钠凝胶贴膏获得药品注册证书
【机构调研记录】兴业基金调研海陆重工、方盛制药
证券之星 · 01-19
【机构调研记录】兴业基金调研海陆重工、方盛制药
每周股票复盘:XD方盛制(603998)2025年特别分红每股0.15元
证券之星 · 01-18
每周股票复盘:XD方盛制(603998)2025年特别分红每股0.15元
方盛制药(603998)发布2025年特别分红权益分派实施公告,1月12日股价下跌2.02%
证券之星 · 01-12
方盛制药(603998)发布2025年特别分红权益分派实施公告,1月12日股价下跌2.02%
方盛制药最新公告:原料药生产转移检查不符合要求但不会对生产经营产生实质性影响
证券之星 · 01-11
方盛制药最新公告:原料药生产转移检查不符合要求但不会对生产经营产生实质性影响
每周股票复盘:方盛制药(603998)拟每股派息0.15元
证券之星 · 01-11
每周股票复盘:方盛制药(603998)拟每股派息0.15元
上会会计师事务所被出具警示函,涉方盛制药年报审计违规
蓝鲸财经 · 01-10
上会会计师事务所被出具警示函,涉方盛制药年报审计违规
方盛制药:截至2025年9月30日股东户数为30993户
证券日报网 · 2025-12-18
方盛制药:截至2025年9月30日股东户数为30993户
方盛制药(603998.SH)通过药品GMP符合性检查
智通财经 · 2025-12-16
方盛制药(603998.SH)通过药品GMP符合性检查
方盛制药(603998.SH):中药创新药养血祛风止痛颗粒纳入国家医保目录
智通财经 · 2025-12-08
方盛制药(603998.SH):中药创新药养血祛风止痛颗粒纳入国家医保目录
6个中成药跻身国家医保目录新增名单,康缘、以岭、三九、方盛各有产品入选
智通财经网 · 2025-12-08
6个中成药跻身国家医保目录新增名单,康缘、以岭、三九、方盛各有产品入选
方盛制药:12月3日接受机构调研,西部证券参与
证券之星 · 2025-12-05
方盛制药:12月3日接受机构调研,西部证券参与
方盛制药:11月19日接受机构调研,中信建投参与
证券之星 · 2025-11-24
方盛制药:11月19日接受机构调研,中信建投参与
每周股票复盘:方盛制药(603998)吲哚布芬片获生产批准
证券之星 · 2025-11-16
每周股票复盘:方盛制药(603998)吲哚布芬片获生产批准
方盛制药(603998.SH):吲哚布芬片获得《药品注册证书》
智通财经 · 2025-11-11
方盛制药(603998.SH):吲哚布芬片获得《药品注册证书》
【机构调研记录】南方基金调研方盛制药、思瑞浦等4只个股(附名单)
证券之星 · 2025-11-10
【机构调研记录】南方基金调研方盛制药、思瑞浦等4只个股(附名单)
加载更多
公司概况
公司名称:
湖南方盛制药股份有限公司
所属行业:
医药制造业
上市日期:
2014-12-05
主营业务:
湖南方盛制药股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是藤黄健骨片、强力枇杷膏(蜜炼)/露、依折麦布片、玄七健骨片、小儿荆杏止咳颗粒、血塞通分散片/片、赖氨酸维B12颗粒、头孢克肟片、金英胶囊、蒲地蓝消炎片。公司先后获评国家火炬计划重点高新技术企业、国家级守合同重信用企业、国家博士后科研工作站、国家认定企业技术中心、国家技术创新示范企业、国家知识产权示范企业、2024年度中国中药研发实力50强、湖南省省长质量奖企业、湖南省绿色工厂、湖南省示范性医药企业、湖南省小巨人计划企业、湖南省质量信用AAA级企业、湖南省心脑血管药物工程技术研究中心、湖南省工业品牌培育示范企业、湖南省产教融合型企业、湖南省疫情防控突出贡献企业、湖南省节水型企业、2022-2023年度中国医药制药业百强、2022-2023年度中国医药行业守法诚信企业、2025年入选湖南省“数字新基建”100个标志性项目、2025年获“国家级绿色工厂”称号。
发行价格:
14.85
{"stockData":{"symbol":"603998","market":"SH","secType":"STK","nameCN":"方盛制药","latestPrice":12.47,"timestamp":1770361200000,"preClose":12.26,"halted":0,"volume":26099300,"delay":0,"changeRate":0.0171,"floatShares":438999999,"shares":438999999,"eps":0.6727,"marketStatus":"已收盘","change":0.21,"latestTime":"02-06 15:00:00","open":12.69,"high":12.88,"low":12.36,"amount":328000000,"amplitude":0.0424,"askPrice":12.5,"askSize":131,"bidPrice":12.47,"bidSize":34,"shortable":0,"etf":0,"ttmEps":0.6727,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":5,"adr":0,"adjPreClose":12.26,"symbolType":"stock","openAndCloseTimeList":[[1770341400000,1770348600000],[1770354000000,1770361200000]],"highLimit":13.49,"lowLimit":11.03,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":439081360,"isCdr":false,"pbRate":3.27,"roa":"--","peRate":18.537238,"roe":"15.71%","epsLYR":0.59,"committee":0.080885,"marketValue":5475000000,"turnoverRate":0.0594,"status":0,"floatMarketCap":5475000000},"requestUrl":"/m/hq/s/603998","defaultTab":"news","newsList":[{"id":"2609321041","title":"方盛制药(603998.SH)控股子公司获得《药品生产许可证》","url":"https://stock-news.laohu8.com/highlight/detail?id=2609321041","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609321041?lang=zh_cn&edition=full","pubTime":"2026-02-05 16:05","pubTimestamp":1770278726,"startTime":"0","endTime":"0","summary":"智通财经APP讯,方盛制药(603998.SH)发布公告,近日,公司控股子公司广东方盛融华药业有限公司(简称“方盛融华”)收到广东省药品监督管理局颁发的《药品生产许可证》,同意方盛融华作为药品上市许可持有人,方盛制药作为受托方,受托产品为瑞卢戈利片。本次获得《药品生产许可证》,有利于公司及子公司整合和分配生产销售资源,提高产能利用率,降低生产成本。本次获得《药品生产许可证》短期内不会对公司业绩产生重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","603998","BK0060"],"gpt_icon":0},{"id":"2608964860","title":"方盛制药(603998)披露并购基金对外出售投资项目部分股份进展公告,2月2日股价下跌1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608964860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608964860?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:40","pubTimestamp":1770043229,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘,方盛制药报收于11.63元,较前一交易日下跌1.44%,最新总市值为51.07亿元。近日,方盛制药发布《关于公司参与投资设立的并购基金对外出售投资项目部分股份的进展公告》。武汉珂信6%股权已过户至同系方盛名下。公司对同系方盛尚有2,085.46万元实缴出资未收回,预计可在年内收回全部剩余出资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"gpt_icon":0},{"id":"2608608077","title":"每周股票复盘:方盛制药(603998)洛索洛芬钠凝胶贴膏获准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2608608077","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608608077?lang=zh_cn&edition=full","pubTime":"2026-02-01 02:49","pubTimestamp":1769885348,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘,方盛制药报收于11.8元,较上周的12.4元下跌4.84%。公司公告汇总2026年1月23日,湖南方盛制药股份有限公司全资子公司广东方盛健盟药业有限公司收到国家药品监督管理局核准签发的《药品注册证书》,洛索洛芬钠凝胶贴膏获准生产。该药品适用于骨关节炎、肌肉痛及外伤后肿胀疼痛的消炎镇痛,主要成分为洛索洛芬钠,剂型为贴膏剂,注册分类为化学药品4类。方盛制药认购2,705万港元,持股比例由50%增至57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","603998"],"gpt_icon":0},{"id":"2606871206","title":"方盛制药(603998)披露关于受让药品上市许可的进展公告,1月28日股价下跌2.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606871206","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606871206?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:17","pubTimestamp":1769609837,"startTime":"0","endTime":"0","summary":"截至2026年1月28日收盘,方盛制药报收于11.93元,较前一交易日下跌2.37%,最新总市值为52.38亿元。该股当日开盘12.19元,最高12.19元,最低11.88元,成交额达1.2亿元,换手率为2.27%。近日,方盛制药发布《关于受让药品上市许可的进展公告》。方盛制药认购2,705万港元,持股比例由50%增至57%。香港方盛堂正分批次对受让的20个药品品种进行技术升级,相关变更手续正在准备中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800042688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"gpt_icon":0},{"id":"2606251871","title":"方盛制药最新公告:洛索洛芬钠凝胶贴膏获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2606251871","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606251871?lang=zh_cn&edition=full","pubTime":"2026-01-25 16:09","pubTimestamp":1769328581,"startTime":"0","endTime":"0","summary":"方盛制药(603998.SH)公告称,1月23日,公司全资子公司健盟药业收到国家药品监督管理局核准签发的《药品注册证书》,洛索洛芬钠凝胶贴膏已获得药品批准文号并可进行生产。洛索洛芬钠凝胶贴膏适用于骨关节炎、肌肉痛及外伤后的肿胀疼痛的消炎、镇痛,有效成分为洛索洛芬钠,属苯丙酸类非甾体抗炎药(NSAID),具有显著的抗炎镇痛作用,尤以镇痛效果为强。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500003400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","603998","BK0239"],"gpt_icon":0},{"id":"2604997009","title":"【机构调研记录】兴业基金调研海陆重工、方盛制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2604997009","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604997009?lang=zh_cn&edition=full","pubTime":"2026-01-19 08:01","pubTimestamp":1768780872,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及1月16日披露的机构调研信息,兴业基金近期对2家上市公司进行了调研,相关名单如下:1)海陆重工 调研纪要:公司主营业务未发生变化,涵盖工业余热锅炉、大型及特种材质压力容器、核安全设备的制造销售,以及固废、废水处理等环境综合治理服务和光伏电站运营。2)方盛制药 调研纪要:公司中药创新药研发进展顺利,多款产品获临床试验批准,部分进入三期临床。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900001822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0035","BK0134","BK0259","002255","BK0077","603998"],"gpt_icon":0},{"id":"2604923910","title":"每周股票复盘:XD方盛制(603998)2025年特别分红每股0.15元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604923910","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604923910?lang=zh_cn&edition=full","pubTime":"2026-01-18 02:50","pubTimestamp":1768675818,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘,XD方盛制报收于11.61元,较上周的11.89元下跌2.35%。本周,XD方盛制1月15日盘中最高价报12.11元。XD方盛制当前最新总市值50.98亿元,在中药板块市值排名42/67,在两市A股市值排名3461/5183。方盛制药2025年特别分红权益分派实施公告公司发布2025年特别分红实施公告,每股派发现金红利0.15元(含税),股权登记日为2026年1月15日,除权(息)日和现金红利发放日为2026年1月16日。本次分红以总股本439,081,360股为基数,合计派发65,862,204元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","603998","BK0239"],"gpt_icon":0},{"id":"2602136955","title":"方盛制药(603998)发布2025年特别分红权益分派实施公告,1月12日股价下跌2.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602136955","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602136955?lang=zh_cn&edition=full","pubTime":"2026-01-12 17:50","pubTimestamp":1768211453,"startTime":"0","endTime":"0","summary":"截至2026年1月12日收盘,方盛制药报收于11.65元,较前一交易日下跌2.02%,最新总市值为51.15亿元。同日,方盛制药发布《2025年特别分红权益分派实施公告》,宣布本次分红派息每股派发现金红利0.15元(含税)。股权登记日为2026年1月15日,除权(息)日和现金红利发放日均为2026年1月16日。本次分红以公司总股本439,081,360股为基数,合计派发现金红利65,862,204元。分红对象为截至股权登记日在中国证券登记结算有限责任公司上海分公司登记在册的全体股东。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200025307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"gpt_icon":0},{"id":"2602665553","title":"方盛制药最新公告:原料药生产转移检查不符合要求但不会对生产经营产生实质性影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2602665553","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602665553?lang=zh_cn&edition=full","pubTime":"2026-01-11 16:39","pubTimestamp":1768120798,"startTime":"0","endTime":"0","summary":"方盛制药公告称,公司收到湖南省药品监督管理局签发的《药品GMP符合性检查告知书》,公司位于湖南望城经济开发区铜官镇循环经济工业基地内的生产地址的检查范围为原料药;原料药车间D区、F区与E区吲哚布芬生产线。经检查,结论为不符合要求,主要系因在中间体1的生产中依据的标准未更新到最新版本导致。公司吲哚布芬原料药及制剂当前处于上市前准备阶段,尚未正式投放市场销售,本次检查不会对公司的生产经营产生实质性影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100005242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0060","BK0239"],"gpt_icon":0},{"id":"2602317535","title":"每周股票复盘:方盛制药(603998)拟每股派息0.15元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602317535","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602317535?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:30","pubTimestamp":1768069826,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘,方盛制药报收于11.89元,较上周的11.24元上涨5.78%。本周,方盛制药1月7日盘中最高价报12.04元。本周关注点公司公告汇总:方盛制药拟实施2025年特别分红,每股派发现金红利0.15元(含税)。公司公告汇总方盛制药关于2025年特别分红的公告湖南方盛制药股份有限公司拟实施2025年特别分红,每股派发现金红利0.15元(含税),以2025年9月30日总股本439,081,360股计算,合计拟派发现金红利65,862,204元,占2025年前三季度归母净利润的24.55%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"gpt_icon":0},{"id":"2602580572","title":"上会会计师事务所被出具警示函,涉方盛制药年报审计违规","url":"https://stock-news.laohu8.com/highlight/detail?id=2602580572","media":"蓝鲸财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602580572?lang=zh_cn&edition=full","pubTime":"2026-01-10 22:02","pubTimestamp":1768053774,"startTime":"0","endTime":"0","summary":"蓝鲸新闻1月10日讯,近日,湖南证监局发布行政监管措施决定书,剑指上会会计师事务所 、刘曙萍、王俊。刘曙萍、王俊作为方盛制药2024年年报审计项目签字会计师,应对上述违规行为负主要责任。对此,湖南证监局决定对上会会计师事务所、刘曙萍、王俊采取出具警示函的监督管理措施,并记入证券期货市场诚信档案。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1768030687813865892","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0239","603998","BK0060"],"gpt_icon":0},{"id":"2592265904","title":"方盛制药:截至2025年9月30日股东户数为30993户","url":"https://stock-news.laohu8.com/highlight/detail?id=2592265904","media":"证券日报网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592265904?lang=zh_cn&edition=full","pubTime":"2025-12-18 21:13","pubTimestamp":1766063580,"startTime":"0","endTime":"0","summary":"证券日报网讯 12月18日,方盛制药在互动平台回答投资者提问时表示,截至2025年9月30日股东户数为30993户。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-18/doc-inhcfvmc8327978.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-18/doc-inhcfvmc8327978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","603998","BK0060"],"gpt_icon":0},{"id":"2591602251","title":"方盛制药(603998.SH)通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2591602251","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591602251?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:45","pubTimestamp":1765874710,"startTime":"0","endTime":"0","summary":"智通财经APP讯,方盛制药(603998.SH)发布公告,近日,公司收到湖南省药品监督管理局签发的《药品GMP符合性检查告知书》,检查范围及相关车间、生产线:1.依折麦布,原料药车间(101车间)B区与E区依折麦布生产线;2.盐酸贝尼地平,原料药车间(101车间)A区与E区盐酸贝尼地平生产线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382085.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"方盛制药(603998.SH)通过药品GMP符合性检查","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","603998","BK0239"],"gpt_icon":0},{"id":"2589733333","title":"方盛制药(603998.SH):中药创新药养血祛风止痛颗粒纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589733333","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589733333?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:51","pubTimestamp":1765183866,"startTime":"0","endTime":"0","summary":"智通财经APP讯,方盛制药(603998.SH)发布公告,公司全资子公司广东方盛健盟药业有限公司独家产品养血祛风止痛颗粒通过谈判首次纳入《国家基本医疗保险、生育保险和工伤保险药品目录》,公司及控股子公司其他主要产品本次无退出及增加至《2025版医保目录》的情况。养血祛风止痛颗粒为公司自主研发的中药创新药,本次经谈判首次被纳入《2025版医保目录》后,将有利于该产品未来的市场推广、医院准入及销售规模的提升,预计对公司未来的经营业绩、市场份额均能产生积极影响,但短期内不会对经营业绩产生重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0060","603998","BK1574","06978","159992","BK1161"],"gpt_icon":0},{"id":"2589803385","title":"6个中成药跻身国家医保目录新增名单,康缘、以岭、三九、方盛各有产品入选","url":"https://stock-news.laohu8.com/highlight/detail?id=2589803385","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589803385?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:31","pubTimestamp":1765164685,"startTime":"0","endTime":"0","summary":"根据国家医保局披露的名单,此次新增的6个中成药品种分别为:温阳解毒颗粒、参郁宁神片、养血祛风止痛颗粒、益气清肺颗粒、玉女煎颗粒、芪防鼻通片,其中包括3个1.1类新药,3个3类新药。","market":"fut","thumbnail":"https://img.zhitongcaijing.com/image/20251208/20251208113159_33210.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251208/20251208113159_33210.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"6个中成药跻身国家医保目录新增名单,康缘、以岭、三九、方盛各有产品入选","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","BK0060","BK0196","BK0175","000999","600557","BK0097","BK0042","002603","BK0183","BK0012","BK0028","BK0185","BK0188","BK0046","BK0010","603998"],"gpt_icon":0},{"id":"2589189535","title":"方盛制药:12月3日接受机构调研,西部证券参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2589189535","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589189535?lang=zh_cn&edition=full","pubTime":"2025-12-05 17:51","pubTimestamp":1764928285,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年12月5日方盛制药发布公告称公司于2025年12月3日接受机构调研,西部证券参与。方盛制药2025年三季报显示,前三季度公司主营收入12.53亿元,同比下降7.02%;归母净利润2.68亿元,同比上升17.6%;扣非净利润2.13亿元,同比上升30.54%;其中2025年第三季度,公司单季度主营收入4.19亿元,同比下降4.26%;单季度归母净利润9904.46万元,同比上升8.49%;单季度扣非净利润7120.39万元,同比上升36.37%;负债率42.2%,投资收益224.18万元,财务费用878.85万元,毛利率71.28%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500028078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0183","BK0276","BK0060","BK0028","603998","BK0188","002673"],"gpt_icon":0},{"id":"2585463818","title":"方盛制药:11月19日接受机构调研,中信建投参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2585463818","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585463818?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:01","pubTimestamp":1763978516,"startTime":"0","endTime":"0","summary":"证券之星消息,2025年11月24日方盛制药发布公告称公司于2025年11月19日接受机构调研,中信建投参与。方盛制药2025年三季报显示,前三季度公司主营收入12.53亿元,同比下降7.02%;归母净利润2.68亿元,同比上升17.6%;扣非净利润2.13亿元,同比上升30.54%;其中2025年第三季度,公司单季度主营收入4.19亿元,同比下降4.26%;单季度归母净利润9904.46万元,同比上升8.49%;单季度扣非净利润7120.39万元,同比上升36.37%;负债率42.2%,投资收益224.18万元,财务费用878.85万元,毛利率71.28%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400023700.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0276","BK0239","603998","601066"],"gpt_icon":0},{"id":"2583519196","title":"每周股票复盘:方盛制药(603998)吲哚布芬片获生产批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2583519196","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583519196?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:35","pubTimestamp":1763235315,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,方盛制药报收于13.01元,较上周的11.98元上涨8.6%。本周,方盛制药11月14日盘中最高价报13.5元,股价触及近一年最高点。方盛制药当前最新总市值57.12亿元,在中药板块市值排名42/67,在两市A股市值排名3057/5165。吲哚布芬片主要用于动脉硬化引起的缺血性心血管病变、缺血性脑血管病变、静脉血栓形成及血液透析时预防血栓形成。截至目前,公司对该药品的研发投入累计约2,872万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0060","BK0239"],"gpt_icon":0},{"id":"2582935626","title":"方盛制药(603998.SH):吲哚布芬片获得《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2582935626","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582935626?lang=zh_cn&edition=full","pubTime":"2025-11-11 16:22","pubTimestamp":1762849334,"startTime":"0","endTime":"0","summary":"智通财经APP讯,方盛制药(603998.SH)发布公告,近日,公司收到国家药品监督管理局(简称“国家药监局”)核准签发的《药品注册证书》,公司研发的吲哚布芬片已获得药品批准文号,并可进行生产。吲哚布芬是一种异吲哚啉基丁酸衍生物,为一种血小板聚集的抑制剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"方盛制药(603998.SH):吲哚布芬片获得《药品注册证书》","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","603998","BK0060"],"gpt_icon":0},{"id":"2582581199","title":"【机构调研记录】南方基金调研方盛制药、思瑞浦等4只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582581199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582581199?lang=zh_cn&edition=full","pubTime":"2025-11-10 08:01","pubTimestamp":1762732884,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及11月7日披露的机构调研信息,南方基金近期对4家上市公司进行了调研,相关名单如下:1)方盛制药 调研纪要:公司通过加强学术推广、深化医院准入和品牌建设应对呼吸类产品阶段性下滑,小儿荆杏止咳颗粒和强力枇杷膏覆盖医疗机构持续扩展。旗下最近一年表现最佳的公募基金产品为南方碳中和股票发起A,最新单位净值为1.45,近一年增长71.6%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000001528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688536","BK0231","SGXZ49509284.SGD","603998","SGXZ81163826.USD","BK0239","BK0060"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770384053507,"stockEarnings":[{"period":"1week","weight":0.0372},{"period":"1month","weight":0.0613},{"period":"3month","weight":0.0364},{"period":"6month","weight":0.1483},{"period":"1year","weight":0.3577},{"period":"ytd","weight":0.1047}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":-0.0019},{"period":"3month","weight":0.0196},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.2621},{"period":"ytd","weight":0.027}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南方盛制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"30993人(较上一季度减少6.50%)","perCapita":"14167股","listingDate":"2014-12-05","address":"湖南省长沙市岳麓区高新区麓松路789号","registeredCapital":"43908万元","survey":" 湖南方盛制药股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是藤黄健骨片、强力枇杷膏(蜜炼)/露、依折麦布片、玄七健骨片、小儿荆杏止咳颗粒、血塞通分散片/片、赖氨酸维B12颗粒、头孢克肟片、金英胶囊、蒲地蓝消炎片。公司先后获评国家火炬计划重点高新技术企业、国家级守合同重信用企业、国家博士后科研工作站、国家认定企业技术中心、国家技术创新示范企业、国家知识产权示范企业、2024年度中国中药研发实力50强、湖南省省长质量奖企业、湖南省绿色工厂、湖南省示范性医药企业、湖南省小巨人计划企业、湖南省质量信用AAA级企业、湖南省心脑血管药物工程技术研究中心、湖南省工业品牌培育示范企业、湖南省产教融合型企业、湖南省疫情防控突出贡献企业、湖南省节水型企业、2022-2023年度中国医药制药业百强、2022-2023年度中国医药行业守法诚信企业、2025年入选湖南省“数字新基建”100个标志性项目、2025年获“国家级绿色工厂”称号。","listedPrice":14.85},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"方盛制药(603998)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供方盛制药(603998)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"方盛制药,603998,方盛制药股票,方盛制药股票老虎,方盛制药股票老虎国际,方盛制药行情,方盛制药股票行情,方盛制药股价,方盛制药股市,方盛制药股票价格,方盛制药股票交易,方盛制药股票购买,方盛制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"方盛制药(603998)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供方盛制药(603998)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}